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Abstract 
Pre-eclampsia is a pregnancy condition affecting 5-10% of 
pregnancies, and it is the leading cause of death in pregnancy 
associated with increased risk of cardiovascular disease later 
in life. Despite research, the pathogenesis of pre-eclampsia is 
still poorly understood. In this paper, we investigate the 
overlapping pathogenic mechanisms between pre-eclampsia 
and adult hypertension using an integrative biomedical 
informatics strategy that combined text mining techniques to 
identify genes and proteins, with geneset analyses, generating 
knowledge on the pathways and mechanisms involved in these 
conditions. We identified several overlapping pathogenic 
pathways/systems including metabolic pathways, 
developmental biology pathways, immune system, haemostasis, 
tyrosine kinase pathways, extracellular matrix and oxidative 
stress pathways. This bioinformatics approach could be 
applied for investigating mechanistic pathways of other 
disorders. 
Keywords:  
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Introduction 
Pre-eclampsia is a condition affecting 5-10% of pregnancies. It 
is clinically characterised by the new onset of hypertension and 
proteinuria or other organ damage after 20 weeks’ gestation  
[1].  There are different types of pre-eclampsia diagnosed 
according to the time of onset in pregnancy, i.e. early (before 
34 weeks’ gestation) and late (after 34 weeks’ gestation) or 
according to the severity of the symptoms [2]. Pre-eclampsia is 
a leading cause of mortality and morbidity, claiming 
approximately 80,000 maternal and 500,000 foetal deaths every 
year [3]. Long-term complications associated with pre-
eclampsia include type 2 diabetes mellitus and cardiovascular 
disease (CVD) for both mothers and adult offspring, later in life 
[4,5].  
During the early stages of pregnancy, a group of differentiated 
cells forming blastocysts, become implanted in the lining of the 
uterus. The outer layer of the blastocyst consists of foetal 
trophoblast cells which invade the spiral uterine arteries after 
implantation [6]. The invasion of trophoblast cells into the 
lining of the uterus results in remodelling of spiral uterine 
arteries to allow an unlimited supply of oxygen and nutrients to 
the foetus. These changes involve the replacement of maternal 
endothelial cells with invasive trophoblasts, which develop to 
form a large section of the placenta, leading to irreversible 
dilation of blood vessels and loss of elastic tissue, therefore 
preventing restriction to blood flow and vasomotor control 
which regulate blood pressure [7]. Impaired trophoblast 
invasion has been implicated in the pathogenesis of pre-
eclampsia. This results in the absence of uteroplacental 
remodelling of spiral arteries leading to placental ischaemia and 
causing insufficient perfusion and delivery of the oxygen and 
nutrients to the foetus which can affect the foetal growth [8]. In 
an attempt to overcome the lack of blood and nutrient supply to 
the foetus, maternal blood pressure becomes gradually 
elevated. The restricted blood supply to the placenta causes the 
release of chemical mediators and hormones into the maternal 
circulation, altering endothelial cell activity and resulting in 
endothelial cell dysfunction. This suppresses the release of 
vasodilatory factors such as nitric oxide (NO) and increases the 
production of vasoconstrictors while inhibiting anticoagulant 
synthesis and increasing procoagulant production [9]. 
Dysbalance of vasodilatory and vasoconstrictive factors 
increases the risk of blood clotting and can lead to an increase 
in blood pressure. Endothelial dysfunction has been implicated 
in the pathogenesis of pre-eclampsia [10,11], however 
endothelial dysfunction following pregnancy complicated by 
severe pre-eclampsia appears to also persist 10-20 years after 
pregnancy [12].  
As mentioned above, women who have pre-ecplampsia and 
their children born from such pregnancies  have increased risk 
of  CVD later in life, particularly if pre-eclampsia was severe 
(blood pressure ≥160/110 mmHg, thrombocytopenia, impaired 
liver function, progressive renal insufficiency, pulmonary 
oedema, and cerebral or visual disturbances). Based on a meta-
analysis of prospective and retrospective cohort studies 
including 198,252 women with pre-eclampsia, the relative risks 
of developing hypertension, ischaemic heart disease and stroke 
were 3.70 after 14.1 years, 2.16 after 11.7 years, 1.81 after 10.4 
years, respectively [13]. Furthermore, children born to mothers 
who suffered pre-eclampsia in pregnancy were also at increased 
risk of hypertension and stroke in later life [14]. 
Pre-eclampsia and cardiovascular disease are affected by 
similar risk factors such as hypertension, obesity, insulin 
resistance, diabetes, a family history of CVD, and genotypes 
related to CVD, suggesting that similar pathogenic mechanisms 
could be present in both diseases [12,15]. Biomarker discovery 
and characterisation is an important area of research both in pre-
eclampsia and CVD that led to the identification of a number of 
important markers. However, despite research in this field, 
there is still a lack of knowledge in relation to the mechanisms 
underpinning the pathogenesis of pre-eclampsia and future 
increased risk of CVD. 
Scientific literature presents the knowledge generated in 
research and practice. It is a continuously growing wealth of 
data that is enriched on a daily base with new publications. 
These data represent an opportunity for the development of 
research strategies aiming to generate new biomedical 
knoweldge that is hidden in this vast amount of information, or 
the generation of new research hypotheses. Therefore, it has 
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attracted the interest of biomedical informatics, especially the 
development of methods and tools designed to mine it. An 
important element of these methodologies has been focused on 
the identification of diseases, genes or proteins cited in 
scientific texts and the identification of interaction networks. 
Biomedical relation extraction is an approach that has shown 
precedence in similar studies providing cross-sectional and 
domain-specific views of biomedical research literature [16–
18]. 
In this study, we investigated an “in silico” approach, which 
uses the information embedded in the literature to integrate 
relevant biomarkers identified in pre-eclampsia and 
hypertension. Furthermore,  we sought to contextualise these in 
terms of significant biological pathways which are common 
denominators in both conditions. The approach presented here 
provides a mechanistic interpretation of the commonalities 
between pre-eclampsia and hypertension, but it could be 
applied to study pathogenesis of any other disorder. 
Methods 
The methodology applied in this work consisted of three 
sequential stages including: i) document search and retrieval, ii) 
document annotation and gene/protein extraction and iii) 
mechanistic analysis. These steps are further detailed below.   
The first step in our analyses included the definition of the 
relevant Pubmed queries, which were used to identify the 
relevant elements in the literature associated with the two 
conditions of interest for this study: 
• Pre-eclampsia query was built as “("pre-
eclampsia"[MeSH Terms] OR "pre-eclampsia"[All 
Fields] OR "preeclampsia"[All Fields]) AND 
("biomarkers"[MeSH Terms] OR "biomarkers"[All 
Fields] OR "biomarker"[All Fields])”. This query 
aimed to retrieve a broad range of elements that could 
be associated with this condition. 
• Hypertension query was built as 
“(Hypertension[MeSH] NOT ("pre-eclampsia"[MeSH 
Terms] OR "pre-eclampsia"[All Fields] OR 
"preeclampsia"[All Fields])) AND Biomarker”. This 
query focused on the retrieval of documents annotated 
as hypertension as a MeSH term while excluding pre-
eclampsia. 
We used the R package RISMed (2.1.7) designed to retrieve and 
download contents from the NCBI databases into R. For this 
purpose, both of these queries were then passed as arguments 
to the function “EUtilsSummary” to identify the relevant 
documents in Pubmed that were subsequently downloaded 
using the “EUtilsGet” function. This resulted in two R data 
frames containing information associated with these documents 
and in particular the relevant Pubmed IDs that were used as 
input in the second stage for annotation of the literature.  
The second stage of the analysis consisted of the annotation of 
the biological terms of relevance (genes/proteins); for this 
purpose, rather than developing a new methodology, we relied 
on the annotations provided by Pubtator [19]. Pubtator 
annotates Pubmed documents using different “named-entity-
recognition” algorithms around four bioconcepts Gene; 
Chemical; Disease; Species. Although Pubtator was initially 
developed as a web service at the NCBI ftp site we used the 
downloadable version of the results from its annotations.    
The third and the final stage consisted of the mechanistic 
analysis of the identified biomarkers. In this analyses we 
selected two knowledge bases to analyse the enrichment in 
certain biological processes or functions: DAVID [20], broad 
and containing multiple annotations such as gene ontology 
terms, Uniprot keywords or KEGG terms for multiple 
organisms; and Reactome [21], a highly curated database of 
biological reactions in humans. Reactome identifies the 
enrichment in its contents using an overrepresentation analysis 
based in the hypergeometric test and using a FDR (Benjamini-
Hochberg) p-value correction to adjust the significance for 
multiple comparisons. DAVID uses EASE, a modified version 
of the hypergeometric test and allows the selection of multiple 
p-value correction methods. In both cases the input provided 
was a list of NCBI Gene IDs that were translated into their own 
internal IDs to match their contents. 
Results 
An overall overview of the methodology developed and the 
results obtained are presented in Figure 1. 
The literature search allowed us to identify and retrieve almost 
9000 documents in total, 3167 for preeclampsia and 5675 for 
hypertension. As a quality control we compared the PMID 
between these two datasets to ensure that there was no overlap 
Figure 1 – Overview of the methodology and the results from the the query terms to the final and total number (sum of Reactome 
and DAVID results) potentially shared pathways and genesets between preeclampsia and hypertension
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and that the results would not be misled by publications present 
in both datasets. 
The annotation of these two sets of Pubmed documents allowed 
us to identify approximately 5,000 different documents that 
were annotated with at least one gene or protein providing 
2,124 in the pre-eclampsia dataset and 3,227 in the 
hypertension dataset. These documents contained 2,386 
genes/proteins of which 446 were present in both datasets (19% 
of the overall gene list and 37% of the genes identified in the 
pre-eclampsia dataset; Figure 2). 
 
Figure 2 – Number of genes/proteins identified for each 
dataset and the set of 446 shared genes proteins that were 
used in the geneset analyses 
Once we identified the relevant gene lists the next step was to 
perform the geneset analyses of the identified genes. As the 
significance is determined by the number of elements in the 
genelist we initially run three different analyses using 
Reactome with the following three subsets: 1- All genes (1624) 
identified for hypertension (HT.a); 2- All genes (1208) 
identified for preeclampsia (PE.a); 3- the 446 genes present in 
both hypertension and preeclampsia (Both). The significance 
threshold for enriched pathways was set as an adjusted p-value 
< 0.05. The number of significant pathways identified in each 
of these analyses are presented in the Table 1 and the shared 
pathways across these comparisons are visualised in Figure 3. 
Table 1 – Number of Reactome pathways significantly 
enriched for each of the three genesets analysed. 
Gene Subset (Number of 
Genes/proteins) (code) 
Number 
of 
Pathways 
Unique 
Pathways 
All genes in Hypertension 
(1624) (HT.a) 20 7 
All genes in Preeclampsia 
(1208) (PE.a) 107 21 
Genes present in both 
Preeclampsia and Hypertension 
(446) (Both) 129 42 
 
The set containing the genes/proteins present in both conditions 
(“Both” set) was the most enriched one with 129 significant 
pathways (Figure 4) whereas the hypertension set, which was 
the largest, was the least enriched with 20 different reactome 
pathways identified. An overlap analysis of these results 
allowed us to identfy 12 pathways in common for the three 
different genesets (Table 2). 
 
Figure 3 – Pathway enrichment for the three analysed sets, 
hypertension (HT.a), pre-eclampsia (PE.a) and the 
intersection between hypertension and pre-eclampsia (both) 
Table 2 – List of the 12 statistically significant (adjusted p-
value <0.05) pathways identified in Reactome for the three 
genesets analysed.  
Pathway Name 
Regulation of Insulin-like Growth Factor (IGF) transport and 
uptake by Insulin-like Growth Factor Binding Proteins 
(IGFBPs) 
Platelet degranulation 
Response to elevated platelet cytosolic Ca2+ 
Post-translational protein phosphorylation  
Platelet activation, signaling and aggregation 
Integrin cell surface interactions  
Chemokine receptors bind chemokines  
Peptide ligand-binding receptors  
Interleukin-10 signaling 
Syndecan interactions 
Formation of Fibrin Clot (Clotting Cascade) 
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling 
 
As different resources contain different information and 
annotations for the different genes we submitted the “both” 
(shared) dataset to DAVID for a complementary analysis. In 
this case we limit the query to the 446 shared elements between 
both pathologies. And set a significance threshold of benjamini 
adjusted p-value < 0.05. This resulted in the detection of 
significant enrichment in 886 different genesets made of 
pathways, gene ontology terms (Table 3) and other annotations. 
Table 3 – List of the top 12  statistically significant (adjusted 
p-value <0.05) Gene Ontology Biologial Process terms 
identifed in DAVID for the intersected gene list 
 
Pathway Name  
 
Pathway Name 
1 Inflammatory response 7 Response to drug
2 Response to hypoxia 8 Platelet degranulation
3 Leukocyte migration 9 Aging 
4 Positive regulation of 
nitric oxide biosyn-
thetic process
10 Positive regulation of 
smooth muscle cell pro-
liferation
5 Positive regulation of 
gene expression
11 Positive regulation of an-
giogenesis
6
Angiogenesis 
12 Regulation of blood pres-
sure  
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Discussion 
Using an integrated strategy we have been able to retrieve 
biomarkers (gene/proteins) that are shared between pre-
eclampsia and hypertension. Our strategy allowed us to also 
identify genes from other organisms commonly used to model 
human diseases such as rats and mice. Although it would have 
been possible to map those genes to their human orthologues 
we decided not to do this therefore keeping our focus just on 
human biomarkers. 
The identified genes were transformed into gene lists that were 
analysed using two different resources. As we mentioned 
before we were focused on human disease or models and, for 
this reason, we chose to run initially a more restrictive search 
using Reactome, as this is a highly curated database used to 
generate results from high-quality and restricted sources 
facilitating their biological interpretation. Overrepresentation 
analyses, similar to what we carried out here, are dependent on 
the size of the query lists and the size of the background 
available in the resource they are compared with. Therefore, 
finding differences in the composition and number of 
significant pathways identified between the lists containing the 
whole set of biomarkers for each condition and their 
intersection, was not completely unexpected. However, it was 
surprising that the smallest list containing the conserved 
biomarkers was the one showing the highest enrichment. From 
a biological perspective, this list, derived from the intersection 
of biomarkers identified in both pathologies, is expected to 
contain genes/proteins positively associated with the diseases. 
These genes would therefore be more biologically meaningful 
and would better capture the common underlying biological 
processes in both conditions.  
The identified pathways for the shared set of genes are related 
to metabolism, developmental biology, immune system, 
haemostasis, tyrosine kinase, extracellular matrix and oxidative 
stress signalling. All these aspects provide coherent and 
meaningful biological information in the context of these 
pathologies. Interestingly, we have identified using DAVID 
analyses, the GO terms associated with “Regulation of blood 
pressure” showing up as statistically significant and highly 
ranked. This is an expected result as both conditions show 
changes in blood pressure, which validates our methodology as 
both conditions share a high blood pressure phenotype. In 
relation to the other enriched pathways identified, for example, 
it is well recognised that inflammation (associated with the 
immune system) plays a significant role in hypertension  
[22,23]. Furthermore, pre-eclampsia is a pregnancy-related 
condition therefore developmental biology plays a key role [6, 
7]. 
Limitations and future work 
The limitations of this study include  some aspects of 
methodology which assume a perfect gene/protein 
identification in the annotation process not taking into the 
account the effects of potential false positive and negative 
biomarker hits. The second limitation is associated with the 
assumption of treating equally all the terms identified and not 
considering potential negations contained in the abstracts. An 
example of this is that we are including a gene in our analysis 
that could appear in the text as “gene XXX does not have an 
effect in pre-eclampsia.” However we tried to minimise this by 
basing our approach on relevant pathways and disease 
mechanisms. 
As part of the future work, we are planning to address 
specifically the effects and quantity of false positives and 
negatives potentially present in the current version and we will 
try to develop new approaches that can help us identify and 
successfully manage negations found in literature used as input.  
In addition to this, as part of the future work, we plan to develop 
an R package that will seamlessly integrate the methodology 
and processes that have been described in this work. 
Finally, we plan to biologically validate some of the findings 
derived from this work. 
Conclusions 
There is a wealth of data and inforamtion available in public 
repositories that could be mined and analysed to generate new 
knowledge and research hypotheses. In this work, we  
combined different biomedical informatics tools, to retrieve 
Figure 4 – Results from the Reactome analysis using the shared elements between pre-eclampsia and hypertension. The 
statistically significant elements are highlighted in yellow in the image.   
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and identify biomarkers in hypertension and pre-eclampsia and 
then analysed these to identifiy common underlying molecular 
mechanisms linking these two conditions. 
This data-driven approach enabled us to identify the specific 
aspects and reactions associated with metabolic pathways, 
developmental biology, immune system, haemostasis, tyrosine 
kinase pathways, extracellular matrix and oxidative stress 
pathways as the most prominently involved in the pathogenesis 
of these two important conditions. 
Our bioinformatics approach described in this paper is   
therefore applicable to any other similar diseases for the 
purpose of identifying overlapping or individual pathogenic 
mechanisms. 
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